Abstract
In summary, this study pioneered the application of stromal cell enucleation technology to repair tissue damage in the reproductive system, explored the potential of cell burial in the treatment of reproductive system diseases and provided a new approach for the clinical treatment of male infertility.
Introduction
Testosterone deficiency (TD) is a prevalent condition among aging men, often manifesting as fatigue, muscle atrophy, and infertility. While Testosterone Replacement Therapy (TRT) is the current standard of care, it is associated with significant risks, including cardiovascular complications and the suppression of endogenous testosterone production. Bone marrow-derived mesenchymal stromal cells (BMSCs) offer a regenerative alternative by potentially replenishing Leydig cells. However, the use of live stem cells carries risks of mal-differentiation and tumorigenesis. This study explores a novel "cell-free" approach using enucleated BMSCs, termed "Cargocytes," to restore testosterone production safely.
Methods: Generation and Characterization of Cargocytes
The researchers developed a method to physically remove the nucleus from BMSCs while preserving essential cytoplasmic machinery. Using Cytochalasin B treatment followed by Ficoll density gradient ultracentrifugation, the nuclei were stripped, leaving behind "Cargocytes." These enucleated cells were characterized to ensure they retained functional organelles, including mitochondria, endoplasmic reticulum, and lysosomes, which are critical for their therapeutic signaling.
Experimental validation confirmed that Cargocytes remained viable for approximately 72 hours. To test their efficacy, the team utilized an Ethane Dimethanesulfone (EDS)-induced rat model of acute testosterone deficiency, where Leydig cells are selectively depleted. Cargocytes were then administered via orthotopic injection into the testes.
Mechanism: Efferocytosis as a Therapeutic Trigger
A key finding of this study is that the therapeutic effect of Cargocytes is driven by their programmed death. Unlike traditional cell therapies that aim for long-term survival, Cargocytes are designed to undergo apoptosis within three days. This rapid turnover triggers efferocytosis—the process by which testicular macrophages engulf apoptotic cells.
This engulfment acts as a biological switch, shifting the macrophage phenotype from a pro-inflammatory M1 state to an anti-inflammatory, pro-healing M2 state. This remodeled immune microenvironment subsequently reactivates the Hedgehog signaling pathway (specifically DHH, SMO, and GLI1), which is essential for the recruitment and maturation of new Leydig cells from the endogenous stem cell niche.
Results: Restoring Reproductive Health
The administration of Cargocytes led to significant physiological recovery in the EDS rat model:
- Hormonal Recovery: Serum testosterone levels in treated rats were significantly elevated by day 14, nearly returning to baseline levels compared to saline-treated controls.
- Leydig Cell Regeneration: There was a marked increase in functional Leydig cell markers, such as $3\beta$-HSD and StAR.
- Spermatogenic Support: The treatment restored the reproductive microenvironment, evidenced by increased expression of spermatogenesis markers including DAZL, SYCP3, and CREM.
- Immune Modulation: Quantitative analysis confirmed a reduction in pro-inflammatory cytokines (IL-6, TNF-\alpha) and an increase in anti-inflammatory factors (IL-10, TGF-\beta).
Discussion and Future Outlook
While Cargocytes present a promising "middle way" between traditional stem cell therapy and purely molecular treatments, several challenges remain. The current enucleation process is labor-intensive, necessitating the development of high-throughput microfluidic methods for clinical scaling. Additionally, while efferocytosis was identified as the primary driver, the specific molecular cargo responsible for Hedgehog pathway activation requires further definition. Future studies should also investigate the long-term stability of the restored testosterone levels beyond the 14-day observation period used in this study.
Conclusion
This study demonstrates that enucleated BMSCs can effectively treat testosterone deficiency by remodeling the immune microenvironment through efferocytosis. By bypassing the safety concerns associated with live stem cell transplantation, Cargocytes offer a novel and potentially safer approach for the clinical management of male infertility and reproductive system damage.
Reference: Sun et al., Reproductive Biology and Endocrinology (2025) 23:21. https://doi.org/10.1186/s12958-025-01352-9
Summary updated